Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Conditions
Keywords
Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer, Peritoneal Cavity Cancer, Stage III Ovarian Epithelial Cancer
Brief summary
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.
Interventions
DRUGplacebo
every 8 hours daily in 28 day cycles
DRUGphenoxodiol
400mg phenoxodiol three times daily in 28 day cycles.
DRUGcarboplatin
AUC=2 weekly in 28 day cycles
Sponsors
MEI Pharma, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin * Recurrent or persistent advanced disease * Have measurable disease * Undergone at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and have responded to the first of those courses of therapy as determined by either Response Evaluation Criteria in Solid Tumors (RECIST) or Gynecologic Cancer Intergroup (GCIG) criteria * Disease relapse as determined by either RECIST or GCIG criteria within 6 months of completion of the second or greater course of platinum therapy using a 2-, 3- or 4-weekly regimen and platinum-free interval of no greater than 6 months at the time of enrollment, being the time taken from the last day of platinum therapy * Any number of previous courses of platinum therapy or non-platinum therapy * Likely to survive at least 3 months * Karnofsky performance score of at least 60% * Have adequate physiological function without evidence of major organ dysfunction as evidenced by: * serum creatinine \< 1.5 mg/dl * serum transaminase levels ≤ 3 x the upper limit of normal (ULN) for the reference laboratory and * bilirubin level \< ULN * Have adequate hematological function defined by: * platelets \> 100,000/mm3 * white cell counts (WCC) \> 3,000/mm3 * neutrophils \> 1,500/mm3 * hemoglobin \> 8.0 g/dl * Aged \> 18 * Be able to understand the risks and benefits of the study and give written informed consent to participation.
Exclusion criteria
* Patients with mucinous histological type of ovarian cancer * Patients who have failed to show a clinical response (RECIST or GCIG criteria) to at least one prior course of platinum therapy * Patients with active infection * Patients with concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, hypertension, ischemic heart disease, congestive heart failure, etc.) * Patients with a history of chronic active hepatitis or cirrhosis * Patients with HIV * Patients with active central nervous system (CNS) metastases. Patients with known CNS metastases must have received prior radiation therapy, and CNS metastatic disease must be stable for 4 weeks. * Patients who have not recovered from the acute effects of any prior anti-neoplastic therapy * Patients with known hypersensitivity to platinum drugs that cannot be managed with concomitant medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death | Progression Free Survival |
Secondary
| Measure | Time frame |
|---|---|
| The secondary efficacy end-point is overall survival (OS) | Overall survival |
Countries
Australia, Belgium, Italy, Poland, Spain, United Kingdom, United States
Outcome results
None listed